Skip to main content

Table 1 Diagnostic and treatment history of the cohort

From: Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?

  History of urothelial CIS History of invasive disease History of intravesical BCG Future urothelial CIS
Urothelial CIS with IHC (n = 22) 10/22 (45%) 10/22 (45%) 12/22 (55%) 5/22 (23%)
Non-neoplastic urothelium with IHC (n = 30) 11/30 (37%) 17/30 (57%) 15/30 (50%) 4/30 (13%)
Urothelial CIS without IHC (n = 20) 6/20 (30%) 8/20 (40%) 7/20 (35%) 10/20 (50%)
  1. BCG, Bacillus Calmette-Guerin; CIS, Carcinoma in situ; IHC, Immunohistochemistry